Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Current Deferred Revenue (2020 - 2025)

Rapid Micro Biosystems' Current Deferred Revenue history spans 6 years, with the latest figure at $5.1 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 5.41% year-over-year to $5.1 million; the TTM value through Sep 2025 reached $5.1 million, down 5.41%, while the annual FY2024 figure was $6.6 million, 10.0% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $5.1 million at Rapid Micro Biosystems, down from $6.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $6.6 million in Q4 2024 and bottomed at $3.3 million in Q4 2021.
  • The 5-year median for Current Deferred Revenue is $4.9 million (2022), against an average of $4.9 million.
  • The largest annual shift saw Current Deferred Revenue decreased 25.0% in 2021 before it soared 42.61% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $3.3 million in 2021, then surged by 42.61% to $4.7 million in 2022, then increased by 27.5% to $6.0 million in 2023, then increased by 10.0% to $6.6 million in 2024, then fell by 23.18% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Current Deferred Revenue are $5.1 million (Q3 2025), $6.1 million (Q2 2025), and $6.1 million (Q1 2025).